2019-06-27T09:22:16-05:00 2018-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 650N BETHESDA MD 208142930 990 2018-01-01 133870223 INTERNATIONAL AIDS VACCINE INITIATIVE INC INTE 2128471111 125 BROAD STREET NO 9TH FL NEW YORK NY 10004 LOUIS D SCHWARTZ CFO 2128471111 2019-06-27 1 3019519090 75.103.231.202 2019-06-27 10:22:09 ED P 0D15A491995E46E808D52BD8C9630571FBE28805 2B7A9914EAA8F2914D3ACF7576175A6968A24A30 2018 2019-02-21 02:37:17Z MARK FEINBERG 125 BROAD STREET NO 9TH FL NEW YORK NY 10004 77192773 0 X WWW.IAVI.ORG X 1996 DE TRANSLATE SCIENTIFIC DISCOVERIES INTO AFFORDABLE, GLOBALLY ACCESSIBLE PUBLIC HEALTH SOLUTIONS 15 14 196 14 0 132012 79435403 75524844 260438 396577 596174 921661 234949 349691 80526964 77192773 17623273 18701603 0 0 27029476 29819824 0 0 1234999 40744716 34861623 85397465 83383050 -4870501 -6190277 81959513 83382669 38044228 46200945 43915285 37181724 X A NONPROFIT SCIENTIFIC RESEARCH ORGANIZATION DEDICATED TO ADDRESSING URGENT, UNMET GLOBAL HEALTH CHALLENGES INCLUDING HIV AND TUBERCULOSIS. THE ORGANIZATION'S MISSION IS TO TRANSLATE SCIENTIFIC DISCOVERIES INTO AFFORDABLE, GLOBALLY ACCESSIBLE PUBLIC HEALTH SOLUTIONS. 0 0 60048929 17668949 RESEARCH AND DEVELOPMENT: THROUGH SCIENTIFIC AND CLINICAL RESEARCH IN AFRICA, INDIA, EUROPE, AND THE U.S., IAVI DEVELOPS VACCINES AND ANTIBODIES IN AND FOR THE DEVELOPING WORLD AND SEEKS TO ACCELERATE THEIR INTRODUCTION IN LOW-INCOME COUNTRIES. IAVI ADVANCES SCIENTIFIC DISCOVERY AND DEVELOPMENT BY FOSTERING UNIQUE COLLABORATIONS AMONG ACADEMIA, INDUSTRY, LOCAL COMMUNITIES, GOVERNMENTS, AND FUNDERS TO EXPLORE NEW AND BETTER WAYS TO ADDRESS PUBLIC HEALTH THREATS THAT DISPROPORTIONATELY AFFECT PEOPLE LIVING IN POVERTY. VACCINE AND ANTIBODY CANDIDATES ARE PUT THROUGH A RIGOROUS PROCESS OF CLINICAL EVALUATION AMONG KEY POPULATIONS TO ESTABLISH THEIR SAFETY AND EFFICACY, AN EFFORT THAT ENABLES IAVI TO STRENGTHEN THE HEALTHCARE INFRASTRUCTURE AND SCIENTIFIC CAPACITY OF COUNTRIES WHERE OUR CLINICAL PARTNERS OPERATE. TO DATE, IAVI AND ITS PARTNERS HAVE ADVANCED MORE THAN 30 HIV VACCINE CANDIDATES INTO EARLY STAGE CLINICAL TRIALS. THIS INCLUDES THE FIRST HIV VACCINE TRIALS IN SUB-SAHARAN COUNTRIES, WHERE THE HIV BURDEN IS GREATEST. IAVI HAS CONDUCTED 47 EPIDEMIOLOGICAL STUDIES AND PROVIDED VOLUNTARY HIV TESTING AND COUNSELING SERVICES TO MORE THAN 790,000 INDIVIDUALS IN AFRICA. IAVI ALSO SUPPORTS PRECLINICAL DEVELOPMENT AND CLINICAL TESTING OF VACCINE CANDIDATES FOR OTHER DISEASES, INCLUDING TUBERCULOSIS AND LASSA FEVER, AS WELL AS ANTIBODY CANDIDATES FOR DISEASE PREVENTION AND TREATMENT. IAVI CONDUCTS TRIALS WITH THE HIGHEST SCIENTIFIC AND ETHICAL STANDARDS TO PROTECT THE RIGHTS, WELL-BEING, AND DIGNITY OF TRIAL VOLUNTEERS. IAVI HAS ALSO LAUNCHED RESEARCH CONSORTIA TO ADDRESS MAJOR SCIENTIFIC PROBLEMS OF BIOMEDICAL PRODUCT DEVELOPMENT. A SIGNIFICANT PORTION OF THE RESEARCH IAVI SUPPORTS IS CONDUCTED IN DEVELOPING COUNTRIES WHERE THE NEED FOR INFECTIOUS DISEASE PREVENTION IS GREATEST. 10062245 396577 CONTRACT MANUFACTURING-RELATED ACTIVITIES: IAVI SUPPORTS EXTERNAL RESEARCHERS BY PROVIDING TECHNICAL AND SCIENTIFIC EXPERTISE TO ACCELERATE THE DEVELOPMENT OF THEIR OWN PRODUCTS. 3431323 1032654 VACCINE ADVOCACY, PUBLIC AFFAIRS, AND POLICY: IAVI WORKS WITH POLICY MAKERS, ADVOCATES, AND REPRESENTATIVES OF THE COMMUNITIES WHERE DISEASE BURDEN IS GREATEST TO SUPPORT SCIENTIFIC RESEARCH AND DEVELOPMENT FOR ACCESSIBLE BIOMEDICAL PREVENTIVES AND TREATMENTS. 73542497 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 0 1 0 1 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 1 0 0 1 X 98 0 1 196 1 1 1 1 IN KE SF UK NL 0 0 0 0 0 0 0 0 0 0 X 15 14 0 0 0 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1 1 0 AL AR CA FL GA HI IL KS KY MD MA MI MN MS NH NJ NM NY NC OR PA RI SC TN UT VA WV WI X X X PATRICK MOUTON 2128471137 125 BROAD STREET NO 9TH FL NEW YORK NY 10004 MARK FEINBERG PRESIDENT/CEO 35.00 X X 553503 0 30769 ERIC PAUL GOOSBY BOARD CHAIR 2.00 X X 0 0 0 ANNE M VANLENT BOARD VICE CHAIR 2.00 X X 0 0 0 ROBERT GOLDBERG BOARD TREASURER 1.00 X X 0 0 0 FRANCINE NTOUMI BOARD MEMBER 1.00 X 0 0 0 MARIJKE WIJNROKS BOARD MEMBER 1.00 X 0 0 0 RAJEEV VENKAYYA BOARD MEMBER (FROM 12/18) 1.00 X 0 0 0 PURNIMA MANE BOARD MEMBER 1.00 X 0 0 0 JIM CONNOLLY BOARD MEMBER (FROM 12/18) 1.00 X 0 0 0 LINDA-GAIL BECKER BOARD MEMBER (FROM 1/18) 1.00 X 0 0 0 CHRISTINA HULL PAXSON BOARD MEMBER (FROM 1/18, UNTIL 6/18) 1.00 X 0 0 0 MARK DYBUL BOARD MEMBER (FROM 3/18) 1.00 X 0 0 0 MONCEF SLAOUI BOARD MEMBER (UNTIL 3/18) 1.00 X 0 0 0 DAVID BLUMBERG BOARD MEMBER (FROM 12/18) 1.00 X 0 0 0 JOHN W SHIVER BOARD MEMBER (FROM 7/18) 1.00 X 0 0 0 ANNE MARTIN SIMONDS BOARD MEMBER (FROM 10/18) 1.00 X 0 0 0 JOHN NKENGASONG BOARD MEMBER (FROM 9/18) 1.00 X 0 0 0 ANA CESPEDES MONTOYA CHIEF OPERATING OFFICER (FROM 9/18) 35.00 X 113846 0 23307 LABEEB ABBOUD SECRETARY, SR VP, GENERAL COUNSEL 35.00 X 378295 0 59950 LOUIS SCHWARTZ CHIEF FINANCIAL OFFICER 35.00 X 324722 0 59950 ANTHONY MUSYOKA H.R., ASST. SECRETARY (UNTIL 8/18) 35.00 X 244969 0 49551 THOMAS HASSELL V.P. VACCINE DEVELOPMENT R&D 35.00 X 345158 0 59950 CHRISTOPHER PARKS EXECUTIVE DIR., VIRAL VACCINES 35.00 X 313102 0 59950 FRANCES PRIDDY EXECUTIVE DIR, CHIEF MEDICAL OFFICER 35.00 X 299146 0 59950 SWATI GUPTA V.P. RESEARCH INTEGRATION & INNOV. 35.00 X 319471 0 57395 MARGARET T KEANE V.P. GLOBAL ALL. & PRODUCT 35.00 X 311679 0 48777 3203891 0 509549 88 0 1 0 EMMES CORPORATION 401 N WASHINGTON STREET ROCKVILLE MD 20850 CLINICAL RESEARCH STUDIES 765799 ROUTES 2 RESULTS 5 PARK CT PYRFORD RD WEST BYFLEET SURREY UK KT1 46SD VIDEO ETHNOGRAPHY 512748 C&G CONSULTING SERVICES INC 186 SAND ROAD FAIRFIELD NJ 07004 TEMP SERVICES 505954 AUSTRALIAN BIOLOGICS PTY LTD PO BOX 587 CRAIGIEBURN VICTORIA AS 3064 REGULATORY CONSULTANT 330878 VEDDER PRICE PC 8677 SOLUTION CENTER CHICAGO IL 606778006 LEGAL SERVICES 188537 13 36081618 39443226 75524844 CONTRACT SERVICE FEES 900099 396577 396577 396577 921661 921661 MISCELLANEOUS 900099 349691 349691 349691 77192773 396577 0 1271352 4961485 4961485 13740118 13740118 1838872 197985 1599988 40899 22497547 18313118 3710285 474144 1679363 1359380 284027 35956 2396967 1913930 429687 53350 1407075 1078822 298324 29929 912699 748931 163768 161221 161221 228050 228050 53575 53575 844497 250730 522131 71636 755974 477125 277703 1146 745879 639497 48284 58098 3504349 2856461 549507 98381 2197854 1926878 223861 47115 335922 281804 42850 11268 1490194 1459401 26255 4538 303611 215489 85137 2985 DISALLOWED FRINGE TAX 30000 30000 RESEARCH&CLINICAL SVCS. 17778408 17753614 694 24100 LAB SUPPLIES/EQUIPMENT 4610263 4610263 EQUIPMENT MAINT. 622942 582028 36254 4660 286185 175438 62003 48744 83383050 73542497 8605554 1234999 49308658 34268115 18982348 17433290 90200 121345 180912 104655 46177971 39763654 7610889 6414317 5601994 24861507 184512 179440 81959513 83382669 5633347 7634830 2210932 2647006 26672679 32676282 269825 191015 3257445 3051812 38044228 46200945 X 29886074 26489768 14029211 10691956 43915285 37181724 81959513 83382669 X -6190277 14673 -557957 X 0 1 X 1 1 1 X 50593210 71447864 63919808 79435403 75524844 340921129 50593210 71447864 63919808 79435403 75524844 340921129 128891460 212029669 775037 694495 538881 596174 921661 3526248 587195 505075 116898 234948 349691 1793807 346241184 1699127 0.61240 0.67160 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: OTHER INCOME - 2014 AMOUNT: $ 70,410. 2015 AMOUNT: $ 146,897. 2016 AMOUNT: $ 54,683. 2017 AMOUNT: $ 100,289. 2018 AMOUNT: $ 232,790. COLLABORATIVE AGREEMENT - 2014 AMOUNT: $ 250,000. RE TAXES REFUND - 2018 AMOUNT: $ 38,091. LOAN FORGIVENESS - 2014 AMOUNT: $ 77,932. 2015 AMOUNT: $ 74,118. 2016 AMOUNT: $ 62,215. 2017 AMOUNT: $ 67,456. 2018 AMOUNT: $ 78,810. WRITE OFF PROVISION FOR RISK - 2014 AMOUNT: $ 188,853. 2015 AMOUNT: $ 284,060. VAT REFUND - 2017 AMOUNT: $ 67,203. 0 228050 228050 83155000 83383050 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 205000 227000 228250 228050 888300 250000 250000 250000 250000 1000000 1500000 20053925 13936937 6116988 26124046 25826717 297329 6414317 DEFERRED RENT 2519984 DEFERRED COMPENSATION PAYABLE 531828 3051812 X 78532653 14673 1378782 1393455 77139198 53575 53575 77192773 83724184 1589094 1589094 82135090 53575 1194385 1247960 83383050 PART X, LINE 2: FOR THE YEAR ENDED DECEMBER 31, 2018, MANAGEMENT OF IAVI HAS DOCUMENTED ITS CONSIDERATION OF FASB ASC 740-10, INCOME TAXES, THAT PROVIDES GUIDANCE FOR REPORTING UNCERTAINTY IN INCOME TAXES AND HAS DETERMINED THAT NO MATERIAL UNCERTAIN TAX POSITIONS QUALIFY FOR EITHER RECOGNITION OR DISCLOSURE IN THE CONSOLIDATED FINANCIAL STATEMENTS. PART XI, LINE 2D - OTHER ADJUSTMENTS: REVENUE OF STICHTING INTERNATIONAL AIDS VACCINE INITIATIVE -27,404. INCLUDED IN CONSOLIDATED AUDIT REPORT BUT EXCLUDED FOR IAVI FORM 990 REPORTING PURPOSES. REVENUE OF IAVI INDIA, INCLUDED IN CONSOLIDATED AUDIT 1,406,186. REPORT BUT EXCLUDED FOR IAVI FORM 990 REPORTING PURPOSES. PART XII, LINE 2D - OTHER ADJUSTMENTS: EXPENSES OF STICHTING INTERNATIONAL AIDS VACCINE INITIATIVE 1,081,832. INCLUDED IN CONSOLIDATED AUDIT REPORT BUT EXCLUDED FOR IAVI FORM 990 REPORTING PURPOSES. EXPENSES OF IAVI INDIA, INCLUDED IN CONSOLIDATED AUDIT 153,550. REPORT BUT EXCLUDED FOR FORM 990 REPORTING PURPOSES. EXPENSES OF AERAS, INCLUDED IN CONSOLIDATED AUDIT 353,712. REPORT BUT EXCLUDED FOR FORM 990 REPORTING PURPOSES. PART XII, LINE 4B - OTHER ADJUSTMENTS: INTER-COMPANY EXPENSES, ELIMINATED IN CONSOLIDATED AUDIT 1,194,385. REPORT BUT INCLUDED IN IAVI, INC. FORM 990. 1 EUROPE 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 6016128 SOUTH ASIA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 263511 SUB-SAHARAN AFRICA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 7450479 NORTH AMERICA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 10000 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 324538 EUROPE 1 6 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 3601714 NORTH AMERICA 0 0 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 261514 SUB-SAHARAN AFRICA 2 27 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 1405950 SOUTH ASIA 1 16 PROGRAM SERVICE ACTIVITIES RESEARCH/ADVOCACY/POLICY 53089 3 33 1 16 4 49 19333834 53089 19386923 EUROPE VACCINE ADVOCACY, PUBLIC AFFAIRS AND POLICY 1032654 WIRE TRANSFER EUROPE RESEARCH&DEVELOPMENT 2898160 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 1442716 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 1464412 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 1104211 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 1122390 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 738844 WIRE TRANSFER EUROPE RESEARCH&DEVELOPMENT 718378 WIRE TRANSFER EUROPE RESEARCH&DEVELOPMENT 547330 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 446186 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 482652 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 386048 WIRE TRANSFER EUROPE RESEARCH&DEVELOPMENT 252711 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 172986 WIRE TRANSFER EUROPE RESEARCH&DEVELOPMENT 137942 WIRE TRANSFER EUROPE RESEARCH&DEVELOPMENT 136648 WIRE TRANSFER SOUTH ASIA RESEARCH&DEVELOPMENT 134274 WIRE TRANSFER EUROPE RESEARCH&DEVELOPMENT 128857 WIRE TRANSFER SOUTH ASIA RESEARCH&DEVELOPMENT 92992 WIRE TRANSFER EUROPE RESEARCH&DEVELOPMENT 76437 WIRE TRANSFER EUROPE RESEARCH&DEVELOPMENT 76025 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 161731 WIRE TRANSFER SOUTH ASIA RESEARCH&DEVELOPMENT 36245 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 27749 WIRE TRANSFER EUROPE RESEARCH&DEVELOPMENT 10985 WIRE TRANSFER NORTH AMERICA RESEARCH&DEVELOPMENT 10000 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 8043 WIRE TRANSFER SUB-SAHARAN AFRICA RESEARCH&DEVELOPMENT 7947 WIRE TRANSFER 24 4 1 0 0 0 0 0 PART I, LINE 2: THE ORGANIZATION HAS A COMPLIANCE UNIT THAT MONITORS THE ADHERENCE OF SUB-GRANTEES TO THE CONTRACT AND DONOR TERMS WHICH INCLUDES REVIEW OF 2 CFR 200 AND THE FAR. ROUTINE COMPLIANCE AND SUBSTANTIVE AUDITS ARE PERFORMED BY A COMPLIANCE OFFICER LOCATED IN EAST AFRICA. ROUTINE INTERNAL CONTROL QUESTIONNAIRES, AND IN-DEPTH REVIEW OF QUARTERLY REPORTS OF SUB-GRANTEES TAKES PLACE ON A REGULAR BASIS. 1 THE SCRIPPS RESEARCH INSTITUTE 10550 NORTH TORREY PINES ROAD LA JOLLA CA 92037 330435954 501(C)(3) 1848541 RESEARCH & DEVELOPMENT INSTITUTE FOR PROTEIN INNOVATION INC 240 LONGWOOD AVENUE BLDG C - ROOM 322 BOSTON MA 02115 813250208 501(C)(3) 894057 RESEARCH & DEVELOPMENT EMORY UNIVERSITY 1599 CLIFTON ROAD ATLANTA GA 30332 580566256 501(C)(3) 715702 RESEARCH & DEVELOPMENT FRED HUTCHINSON CANCER RESEACH CENTER 1100 FAIRVIEW AVENUE NORTH SEATTLE WA 98109 237156071 501(C)(3) 425342 RESEARCH & DEVELOPMENT SEATTLE BIOMEDICAL RESEARCH INSTITUTE 307 WETLAKE AVENUE N STE 500 SEATTLE WA 981095240 910961784 501(C)(3) 281134 RESEARCH & DEVELOPMENT UNIVERSITY OF ALABAMA AT BIRMINGHAM 701 20TH STREET S-AB 921 BIRMINGHAM AL 35294 636005396 501(C)(3) 170670 RESEARCH & DEVELOPMENT UNIVERSITY OF CALIFORNIA SAN FRANCISCO 3333 CALIFORNIA STREET SUITE 315 SAN FRANCISCO CA 94158 943067788 501(C)(3) 150396 RESEARCH & DEVELOPMENT GEORGE WASHINGTON UNIVERSITY 45155 RESEARCH PLACE - STE 160 ASHBURN VA 20147 530196584 501(C)(3) 140938 RESEARCH & DEVELOPMENT NORTHWESTERN UNIVERSITY 750 N LAKE SHORE DRIVE 7TH FLOOR CHICAGO IL 60611 362167817 501(C)(3) 138526 RESEARCH & DEVELOPMENT NATIONAL INSTITUTE OF ALLERGY-INFECTIOUS DISEASES 6610 ROCKLEDGE DRIVE RM 2800 BETHESDA CA 208926606 530196960 GOVERNMENT 100000 RESEARCH & DEVELOPMENT SEATTLE CHILDREN'S HOSPITAL 4800 SAND POINT WAY NE SEATTLE WA 98105 910961784 501(C)(3) 45403 RESEARCH & DEVELOPMENT UNIVERSITY OF WISCONSIN-MADISON 21 N PARK STREET STE 6401 MADISON WI 537151218 366006492 501(C)(3) 24375 RESEARCH & DEVELOPMENT CHILDREN'S HOSPITAL OF PHILADELPHIA 3535 MARKET STREET 12TH FLOOR PHILADELPHIA PA 19104 231352166 501(C)(3) 15108 RESEARCH & DEVELOPMENT 13 0 PART I, LINE 2: THE ORGANIZATION HAS A COMPLIANCE UNIT THAT MONITORS THE ADHERENCE OF SUB-GRANTEES TO THE CONTRACT AND DONOR TERMS WHICH INCLUDES REVIEW OF 2 CFR 200 AND THE FAR. REVIEW OF 2 CFR 200 AUDITS AND IN-DEPTH REVIEW OF QUARTERLY REPORTS OF SUB-GRANTEES TAKES PLACE ON A REGULAR BASIS. X X X X X 1 0 0 0 0 0 0 1 0 MARK FEINBERG PRESIDENT/CEO 501411 0 45788 0 6304 0 30250 0 519 0 584272 0 0 0 LABEEB ABBOUD SECRETARY, SR VP, GENERAL COUNSEL 331754 0 25851 0 20690 0 30250 0 29700 0 438245 0 0 0 LOUIS SCHWARTZ CHIEF FINANCIAL OFFICER 296364 0 26102 0 2256 0 30250 0 29700 0 384672 0 0 0 ANTHONY MUSYOKA H.R., ASST. SECRETARY (UNTIL 8/18) 182151 0 18193 0 44625 0 19851 0 29700 0 294520 0 0 0 THOMAS HASSELL V.P. VACCINE DEVELOPMENT R&D 315615 0 27353 0 2190 0 30250 0 29700 0 405108 0 0 0 CHRISTOPHER PARKS EXECUTIVE DIR., VIRAL VACCINES 291513 0 19783 0 1806 0 30250 0 29700 0 373052 0 0 0 FRANCES PRIDDY EXECUTIVE DIR, CHIEF MEDICAL OFFICER 277302 0 20428 0 1416 0 30250 0 29700 0 359096 0 0 0 SWATI GUPTA V.P. RESEARCH INTEGRATION & INNOV. 292944 0 24775 0 1752 0 30250 0 27145 0 376866 0 0 0 MARGARET T KEANE V.P. GLOBAL ALL. & PRODUCT 267195 0 29250 0 15234 0 29477 0 19300 0 360456 0 0 0 PART I, LINE 4A ANTHONY MUSYOKA RECEIVED SEVERANCE OF $43,706 PURSUANT TO IAVI'S SEVERANCE POLICY. PART I, LINE 7 BONUS COMPENSATION HAS BEEN REFLECTED IN PART II, COLUMN (B)(II). NOODLE FOX MEDIA THE OWNER OF THE ENTITY IS A FAMILY MEMBER (SPOUSE) OF AN OFFICER OF IAVI. 149527 IAVI HAS A CONSULTING AGREEMENT WITH NOODLE FOX MEDIA, TO PROVIDE MANAGING EDITOR SERVICES FOR IAVI REPORT. THE CONSULTANT WAS SELECTED ON A SOLE SOURCE BASIS, DUE TO UNIQUE SKILL AND EXPERIENCE. THE CONSULTANT HAD PREVIOUSLY SERVED AT IAVI AS MANAGING EDITOR FOR IAVI REPORT, AND BROUGHT RELEVANT SUBSTANTIVE KNOWLEDGE, SCIENTIFIC CONTACTS, AND EXPERTISE IN SCIENCE WRITING, EDITING AND MANAGING THE PUBLICATION PROCESS. THE AGREEMENT WAS ESTABLISHED ON AN ARMS-LENGTH BASIS BY THE ORGANIZATION. 0 DESMOND TUTU HIV FOUNDATION AN IAVI BOARD MEMBER IS THE DEPUTY DIRECTOR AND COO OF THE ENTITY. 209856 IAVI HAS A SUB-AWARD AGREEMENT WITH DESMOND TUTU INSTITUTE FOR HIV RESEARCH FOUNDATION. 0 FORM 990, PART VI, SECTION B, LINE 11B THE AUDIT AND FINANCE COMMITTEE REVIEWED AND APPROVED THE FORM 990 IN DETAIL WITH THE CONTROLLER AND CFO. IT WAS THEN SENT TO THE FULL BOARD BEFORE IT WAS FILED WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C IAVI HAS A CONFLICT OF INTEREST POLICY WHICH APPLIES TO ALL DIRECTORS, OFFICERS, KEY PERSONS, EMPLOYEES, CONSULTANTS AND ADVISORY COMMITTEE MEMBERS. THE POLICY REQUIRES THAT ALL DIRECTORS, OFFICERS, KEY PERSONS, EMPLOYEES AND ADVISORY COMMITTEE MEMBERS FILE AN ANNUAL DISCLOSURE FORM, INDICATING WHETHER THERE ARE ANY POSSIBLE OR ACTUAL CONFLICTS AS DEFINED UNDER THE POLICY. IN ADDITION, ALL ARE REQUIRED TO DISCLOSE ANY POSSIBLE OR ACTUAL CONFLICTS ON AN ONGOING BASIS. ANNUAL DISCLOSURE FORMS, AS WELL OTHER CONFLICT OF INTEREST DISCLOSURES THAT ARISE DURING THE YEAR, ARE FILED WITH AND REVIEWED BY THE GENERAL COUNSEL'S OFFICE. IN ADDITION, THE AUDIT & FINANCE COMMITTEE REVIEWS CONFLICT OF INTEREST DISCLOSURES THAT INVOLVE A DIRECTOR, OFFICER, OR KEY PERSON. IN EACH CASE, THE REVIEW ENSURES THAT ANY CONFLICT OF INTEREST OR POSSIBLE CONFLICT OF INTEREST IS PROPERLY ADDRESSED, MITIGATED, AND/OR MANAGED. CONFLICT OF INTEREST DISCLOSURES ARE SUMMARIZED AND PROVIDED TO THE CHAIR OF THE AUDIT & FINANCE COMMITTEE FOR REVIEW BY THE AUDIT & FINANCE COMMITTEE. IF ANY CONFLICT OF INTEREST OR POSSIBLE CONFLICT OF INTEREST DISCLOSURE INVOLVES THE CHAIR OF THE AUDIT & FINANCE COMMITTEE, THE COMMITTEE MEETS WITHOUT THE CHAIR. FORM 990, PART VI, SECTION B, LINE 15 ONCE EVERY TWO YEARS, THE COMPENSATION COMMITTEE OF THE BOARD, COMMISSIONS A COMPENSATION SURVEY OF THE CEO'S COMPENSATION PACKAGE. THE SURVEY COMPARES COMPENSATION PACKAGES OF CEOS OF ORGANIZATIONS THAT ARE COMPARABLE TO IAVI. THE COMMITTEE REVIEWS THE RESULTS OF THE SURVEY AND RECOMMENDATIONS MADE, DISCUSSES THIS WITH THE BOARD BEFORE PROVIDING SPECIFIC GUIDANCE AND APPROVAL TO IAVI'S MANAGEMENT. THE COMPENSATION COMMITTEE DETERMINES THE APPROPRIATE PACKAGE FOR THE CEO AND THE BOARD CHAIR SHARES THIS INFORMATION WITH HUMAN RESOURCES FOR IMPLEMENTATION. IAVI ENGAGES AN EXTERNAL SPECIALIZED FIRM WITH EXPERTISE TO CONDUCT THE SURVEY AND PROVIDE RECOMMENDATION TO THE COMPENSATION COMMITTEE. THE DELIBERATIONS OF THE COMPENSATION COMMITTEE OF THE BOARD ARE DOCUMENTED IN THE COMPENSATION COMMITTEE MINUTES FOR EACH MEETING OF THE MEMBERS. ALSO THE SAME IS CAPTURED IN THE BOARD MINUTES AS REPORTED OUT BY THE COMPENSATION COMMITTEE CHAIR FOR BOARD DISCUSSIONS AND APPROVAL. THE LAST COMPENSATION REVIEW TOOK PLACE IN DECEMBER 2018. IN CONJUNCTION WITH THE CEO'S COMPENSATION REVIEW, THE COMPENSATION COMMITTEE OF THE BOARD ALSO COMMISSIONS AN EXTERNAL COMPARATIVE COMPENSATION SURVEY OF ORGANIZATIONS SIMILAR TO IAVI, IN WHICH THE PACKAGES OF ALL OTHER OFFICERS AND KEY EMPLOYEES ARE BENCHMARKED AGAINST THE LABOR MARKET TO DETERMINE APPROPRIATENESS OF PAY. THE COMMITTEE REVIEWS THE RESULTS AND RECOMMENDATIONS FROM THIS SURVEY AND PROVIDES MANAGEMENT WITH SPECIFIC GUIDANCE IN ADDRESSING ANY DISPARITIES. USING BENCHMARK JOB CLASSIFICATIONS, ONCE EVERY 2 YEARS IAVI COMMISSIONS A COMPENSATION SURVEY, ACROSS ALL ITS OFFICES TO DETERMINE THE COMPETITIVENESS OF ITS COMPENSATION PROGRAMS AND TO ENABLE THE ORGANIZATION TO CONTINUE TO ATTRACT AND RETAIN THE RIGHT TALENT IN THESE VARIOUS MARKETS. IN MOST CASES THE LOCAL LABOR MARKET IS CONSIDERED AND FOR CERTAIN POSITIONS, REGIONAL MARKETS MUST BE TARGETED. THE RESULTS OF EACH SURVEY ARE REVIEWED WITH THE COMPENSATION COMMITTEE OF THE BOARD, WHICH GIVES MANAGEMENT OVERALL GUIDANCE ON COMPENSATION DIRECTION. BASED ON RECOMMENDATIONS AND GUIDANCE OF THE COMPENSATION COMMITTEE, THE EXECUTIVE OFFICE AND HUMAN RESOURCES COMMUNICATE CHANGES TO ANY AFFECTED EMPLOYEES. ANY COMPENSATION CHANGES ARE DETERMINED BASED ON EXTERNAL COMPETIVENESS RELATIVE INTERNAL VALUE, INDIVIDUAL PERFORMANCE, TEAM DYNAMIC, AND IAVI'S ABILITY TO PAY. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE ON ITS WEBSITE. FORM 990, PART XI, LINE 9: FOREIGN EXCHANGE LOSS -604,253. GRANT TO AERAS ELIMINATED IN CONSOLIDATION 46,296. IAVI LAB LLC 125 BROAD STREET 9TH FL NEW YORK NY 10004 262031769 LAB RESEARCH DE 0 5407738 IAVI INC STICHTING IAVI VAN DIEMENSTRAAT 48 1013 NH AMSTERDAM NL RESEARCH SUPPORT NL N/A N/A IAVI INC 1 IAVI INDIA 4 FACTORY ROAD GROUND FLOOR ANSARI NAGAR WEST NEW DELHI-110029 IN RESEARCH SUPPORT IN N/A N/A IAVI INC 1 AERAS GLOBAL TB VACCINE FOUNDATION NPC BLACK RIVER PARK 2 FIR ST OBSERVA CAPETOWN SF RESEARCH SUPPORT SF N/A N/A IAVI INC 1 IAVI HOLDING LLC 125 BROAD STREET 9TH FL NEW YORK NY 10004 262032322 HOLDING COMPANY DE IAVI INC C 1.00000 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 STICHTING IAVI B 1032654 ACTUAL AERAS GLOBAL TB VACCINE FOUNDATION NPC B 161731 ACTUAL SCHEDULE R, PART II: EFFECTIVE AS OF OCTOBER 1, 2018, IAVI COMPLETED AN ACQUISITION OF THE MAJORITY OF THE REMAINING ASSETS OF AERAS, A NON-PROFIT CORPORATION FORMED UNDER THE LAWS OF THE DISTRICT OF COLUMBIA, THAT HAS FOCUSED ON THE ADVANCEMENT OF TB VACCINE RESEARCH AND DEVELOPMENT AND IAVI ALSO ASSUMED CONTROL OF AN AERAS AFFILIATED ENTITY IN SOUTH AFRICA, THE AERAS GLOBAL TB VACCINE FOUNDATION (AERAS S.A.), THROUGH THE ASSUMPTION OF CONTROL OVER THE APPOINTMENT OF THE DIRECTORS OF THE SOUTH AFRICAN ENTITY. THE PURPOSE OF THE ASSET TRANSFER WAS TO ACQUIRE THE REMAINING TB VACCINE PROGRAMS OF AERAS, INCORPORATE THEM INTO IAVI IN A MANNER THAT WOULD STRENGTHEN IAVI'S GLOBAL CLINICAL DEVELOPMENT CAPABILITIES AND ENABLE IAVI TO ADVANCE THE CLINICAL DEVELOPMENT OF TB VACCINE CANDIDATES. THE ASSET TRANSFER WAS EFFECTED THROUGH AN ASSET TRANSFER AGREEMENT (ATA) DATED AS OF SEPTEMBER 30, 2018, BETWEEN AERAS AND IAVI. PURSUANT TO THE ATA, IAVI ACQUIRED THE RIGHT, TITLE AND INTEREST TO THE MAJORITY OF THE REMAINING AERAS' ASSETS, AS OF THE EFFECTIVE DATE, WHICH INCLUDED THE REMAINING PROGRAMMATIC ACTIVITIES, PROPERTIES, GOODWILL AND RIGHTS OWNED, LEASED OR LICENSED BY AERAS. AS OF DECEMBER 2018, IAVI APPOINTED TWO OF THE AERAS DIRECTORS TO THE IAVI BOARD OF DIRECTORS. IAVI DID NOT MAKE ANY PAYMENT TO AERAS IN CONNECTION WITH THE ACQUISITION OF THE AERAS ASSETS. IAVI DID RECEIVE CERTAIN FINANCIAL ASSETS (INCLUDING FINANCIAL PAYMENTS) FROM AERAS IN CONNECTION WITH THE ATA.